免疫系统
生物
转录组
主要组织相容性复合体
浆液性液体
卵巢癌
计算生物学
T细胞
癌症研究
抗原
细胞
MHC I级
T细胞受体
肿瘤微环境
图谱
生物信息学
清除单元格
癌症
免疫学
卵巢癌
医学
作者
Fernando Perez-Villatoro,Aleksandra Shabanova,Lilian van Wagensveld,Ada Junquera,Iga Niemiec,María Mercedes Hincapié-Otero,Ziqi Kang,Matías Marín Falco,Kürşat Birgin,Sarah Wolf,Ella Anttila,Gayani Anandagoda,Julia Casado,Eric Marcus,Duco Gaillard,Essi Kahelin,Foteini Chamchougia,Matilda Salko,Saundarya Shah,Salvatore Russo
出处
期刊:Cancer Discovery
[American Association for Cancer Research]
日期:2026-02-09
卷期号:16 (6): 1100-1125
被引量:1
标识
DOI:10.1158/2159-8290.cd-25-1492
摘要
The tumor microenvironment in high-grade serous ovarian carcinoma (HGSC) is a complex network of malignant-host cell interactions, yet its orchestration remains poorly understood. We present a single-cell spatial atlas of metastatic HGSC from 280 patients, integrating high-dimensional imaging and molecular profiling. Analyzing 929 single-cell maps, we identify spatial domains with diverse cell compositions and show that immune cell coinfiltration at the tumor-stroma interface affects clinical outcomes. Using Cell Feature Importance Identification by RAndom forest (CEFIIRA), we find that tumor cell MHC class II (MHCII) expression is a key predictor of prolonged survival. Validation with deconvoluted single-cell and two distinct spatial transcriptomic datasets, along with immunopeptidomic analysis, confirms that MHCII expression correlates with immune activation, antigen presentation, and T-cell receptor clonality. Using a patient-derived immuno-oncology platform, we demonstrate that tumor MHCII expression associates with increased CD8+ T-cell cytotoxicity after PD-1 blockade, whereas blocking MHCII inhibits this activation. Our atlas offers new insights into immune activation, potentially improving patient stratification in HGSC. SIGNIFICANCE: This study delivers the first large-scale single-cell spatial atlas of HGSC, revealing how tumor-immune organization shapes outcomes. We identify tumor-intrinsic MHCII as a key driver of local immune activation and immunotherapy responsiveness, providing a mechanistic biomarker that can immediately inform improved patient stratification and therapeutic decision-making in ovarian cancer. See related commentary by Conejo-Garcia and Dangaj Laniti, p. 1041.
科研通智能强力驱动
Strongly Powered by AbleSci AI